Spago Nanomedical AB AI Stock Analysis
Want to see SE:SPAGO full AI Analyst Report?
Spago Nanomedical AB (SPAGO) AI Stock Analysis
Spago Nanomedical AB
(Nasdaq OMX AB:SPAGO)
The overall score of 40 reflects a very high-risk, pre-revenue biotechnology company. The most significant factor is the extremely weak financial performance, characterized by negligible revenue and a dangerously high cash burn rate that threatens the company's survival without new funding. This is compounded by a persistently bearish technical trend, with the stock price in a clear downtrend below all key moving averages. The debt-free balance sheet provides a small buffer, but it is rapidly eroding.
Spago Nanomedical AB (SPAGO) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 33.21M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.00M
- Price to Earnings (P/E)
- -1.0
- Beta (1Y)
- 1.34
- Revenue Growth
- -97.52%
- EPS Growth
- 31.31%
- Country
- Sweden
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Spago Nanomedical AB Business Overview & Revenue Model
Company Description
Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gado...
How the Company Makes Money
Spago Nanomedical AB is primarily a development-stage company. null
Spago Nanomedical AB Financial Statement Overview
Summary
Financial health is critically weak. The income statement shows virtually no revenue ($26K TTM) and massive operating losses, while cash flow is deeply negative (-$25.6M TTM operating cash flow) indicating rapid cash burn. The balance sheet is the only relative bright spot due to zero debt, but equity is eroding quickly. This is a pre-revenue company with unsustainable operations.
Income Statement
8Very NegativeBalance Sheet
45NeutralCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.00K | 437.00K | 1.91M | 1.20M | 1.05M | 660.00K |
| Gross Profit | -14.23M | -19.38M | -12.36M | -23.28M | -15.60M | -16.78M |
| EBITDA | -26.99M | -26.39M | -33.40M | -42.22M | -38.73M | -38.69M |
| Net Income | -24.40M | -26.55M | -32.51M | -42.22M | -39.31M | -39.08M |
Balance Sheet | ||||||
| Total Assets | 31.20M | 36.68M | 39.58M | 52.98M | 205.95M | 191.62M |
| Cash, Cash Equivalents and Short-Term Investments | 24.52M | 29.67M | 32.47M | 45.22M | 62.10M | 52.46M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 6.12M | 5.94M | 6.35M | 11.67M | 8.80M | 6.81M |
| Stockholders Equity | 25.07M | 30.75M | 33.23M | 41.32M | 197.16M | 184.81M |
Cash Flow | ||||||
| Free Cash Flow | -9.44M | -28.53M | -34.90M | -45.06M | -42.02M | -40.20M |
| Operating Cash Flow | -25.59M | -28.30M | -34.67M | -44.91M | -38.19M | -35.57M |
| Investing Cash Flow | -443.00K | 633.00K | -230.00K | -506.00K | -3.83M | -4.63M |
| Financing Cash Flow | 39.29M | 24.87M | 22.15M | 28.53M | 51.66M | 64.21M |
Spago Nanomedical AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPAGO, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.08, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 32.41 is Neutral, neither overbought nor oversold. The STOCH value of 32.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SPAGO.
Spago Nanomedical AB Peers Comparison
Overall Rating
SE:CANTA83Outperform
SE:IMMU48Neutral
SE:XSPRAY43Neutral
SE:BIOVIC.B41Neutral
SE:SPAGO40Underperform
SE:FLUO40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | SEK 360.89M | 1.90 | 63.09% | ― | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | SEK 217.58M | -1.96 | -19.14% | ― | ― | 13.06% | |
| 43Neutral | SEK 596.31M | -2.96 | -25.14% | ― | ― | 40.78% | |
| 41Neutral | SEK 86.64M | -1.21 | -75.51% | ― | 56.06% | 63.95% | |
| 40Underperform | SEK 33.21M | -1.03 | -87.37% | ― | -97.52% | 31.31% | |
| 40Underperform | SEK 482.30M | -6.55 | ― | ― | ― | -23.57% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:SPAGO | Spago Nanomedical AB | 0.04 | -0.05 | -56.84% | |
| SE:BIOVIC.B | Biovica International AB Class B | 0.30 | -0.27 | -47.18% | |
| SE:XSPRAY | Xspray Pharma AB | 10.18 | -13.96 | -57.83% | |
| SE:IMMU | Immunicum AB | 3.50 | -1.49 | -29.79% | |
| SE:CANTA | Cantargia AB | 1.29 | -1.94 | -60.03% | |
| SE:FLUO | FluoGuide A/S | 29.50 | -8.50 | -22.37% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
